Evaluation of clinical activity and safety of Daflon 500 mg in type 2 diabetic female patients
Identifieur interne : 003193 ( Pmc/Corpus ); précédent : 003192; suivant : 003194Evaluation of clinical activity and safety of Daflon 500 mg in type 2 diabetic female patients
Auteurs : Sherine Maher Rizk ; Nagwa Ali SabriSource :
- Saudi Pharmaceutical Journal : SPJ [ 1319-0164 ] ; 2009.
Abstract
The incidence of cardiovascular disease in patients with type 2 diabetes mellitus is approximately twice as high as in the non-diabetic population.
To investigate the hypoglycemic and hypocholesterolemic effects of Daflon® 500 mg (DF) administration together with its tolerability and efficacy in reducing the cardiovascular metabolic risk factors in female patients with type 2 diabetes.
In a well-adequate controlled single-blinded randomized parallel design the tolerability and the efficacy of Daflon® (500 mg) either alone or with oral hypoglycemic, twice daily for 45 days, was studied in 36 female patients with type 2 diabetes.
None of the patients in the studied groups were reported to have any adverse events throughout the treatment period (45 days), liver and kidney function tests were within normal limits and there was no significant difference between the pre-treatment (day 0) and post-treatment (day 45) values. Female patients receiving Daflon® either alone or with oral hypoglycemic showed significant decrease in serum glucose; fructosamine; total cholesterol; LDL–cholesterol; triglycerides; malondialdehydes (as index of lipid peroxidation) and C-reactive protein (CRB) levels along with increase in the levels of nitric oxide and blood glutathione.
This study has shown that Daflon® (500 mg, twice daily for 45 days) is helpful in reducing glucose level and the risk of cardiovascular disease in type 2 diabetic patients.
Further clinical trials are essential for strengthening the evidence base on the role of this drug in the cardiovascular risk in diabetic patients.
Url:
DOI: 10.1016/j.jsps.2009.08.008
PubMed: 23964162
PubMed Central: 3731024
Links to Exploration step
PMC:3731024Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of clinical activity and safety of Daflon 500 mg in type 2 diabetic female patients</title><author><name sortKey="Rizk, Sherine Maher" sort="Rizk, Sherine Maher" uniqKey="Rizk S" first="Sherine Maher" last="Rizk">Sherine Maher Rizk</name><affiliation><nlm:aff id="aff1">Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt</nlm:aff></affiliation></author><author><name sortKey="Sabri, Nagwa Ali" sort="Sabri, Nagwa Ali" uniqKey="Sabri N" first="Nagwa Ali" last="Sabri">Nagwa Ali Sabri</name><affiliation><nlm:aff id="aff2">Department of Clinical Pharmacy, Ain Shams University, Cairo, Egypt</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23964162</idno><idno type="pmc">3731024</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731024</idno><idno type="RBID">PMC:3731024</idno><idno type="doi">10.1016/j.jsps.2009.08.008</idno><date when="2009">2009</date><idno type="wicri:Area/Pmc/Corpus">003193</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003193</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Evaluation of clinical activity and safety of Daflon 500 mg in type 2 diabetic female patients</title><author><name sortKey="Rizk, Sherine Maher" sort="Rizk, Sherine Maher" uniqKey="Rizk S" first="Sherine Maher" last="Rizk">Sherine Maher Rizk</name><affiliation><nlm:aff id="aff1">Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt</nlm:aff></affiliation></author><author><name sortKey="Sabri, Nagwa Ali" sort="Sabri, Nagwa Ali" uniqKey="Sabri N" first="Nagwa Ali" last="Sabri">Nagwa Ali Sabri</name><affiliation><nlm:aff id="aff2">Department of Clinical Pharmacy, Ain Shams University, Cairo, Egypt</nlm:aff></affiliation></author></analytic><series><title level="j">Saudi Pharmaceutical Journal : SPJ</title><idno type="ISSN">1319-0164</idno><idno type="eISSN">2213-7475</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>The incidence of cardiovascular disease in patients with type 2 diabetes mellitus is approximately twice as high as in the non-diabetic population.</p></sec><sec><title>Aim</title><p>To investigate the hypoglycemic and hypocholesterolemic effects of Daflon<sup>®</sup> 500 mg (DF) administration together with its tolerability and efficacy in reducing the cardiovascular metabolic risk factors in female patients with type 2 diabetes.</p></sec><sec><title>Methods</title><p>In a well-adequate controlled single-blinded randomized parallel design the tolerability and the efficacy of Daflon<sup>®</sup> (500 mg) either alone or with oral hypoglycemic, twice daily for 45 days, was studied in 36 female patients with type 2 diabetes.</p></sec><sec><title>Results</title><p>None of the patients in the studied groups were reported to have any adverse events throughout the treatment period (45 days), liver and kidney function tests were within normal limits and there was no significant difference between the pre-treatment (day 0) and post-treatment (day 45) values. Female patients receiving Daflon<sup>®</sup> either alone or with oral hypoglycemic showed significant decrease in serum glucose; fructosamine; total cholesterol; LDL–cholesterol; triglycerides; malondialdehydes (as index of lipid peroxidation) and C-reactive protein (CRB) levels along with increase in the levels of nitric oxide and blood glutathione.</p></sec><sec><title>Conclusion</title><p>This study has shown that Daflon<sup>®</sup> (500 mg, twice daily for 45 days) is helpful in reducing glucose level and the risk of cardiovascular disease in type 2 diabetic patients.</p></sec><sec><title>Recommendation</title><p>Further clinical trials are essential for strengthening the evidence base on the role of this drug in the cardiovascular risk in diabetic patients.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Saudi Pharm J</journal-id><journal-title-group><journal-title>Saudi Pharmaceutical Journal : SPJ</journal-title></journal-title-group><issn pub-type="ppub">1319-0164</issn><issn pub-type="epub">2213-7475</issn></journal-meta><article-meta><article-id pub-id-type="pmid">23964162</article-id><article-id pub-id-type="pmc">3731024</article-id><article-id pub-id-type="publisher-id">SPJ1</article-id><article-id pub-id-type="doi">10.1016/j.jsps.2009.08.008</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of clinical activity and safety of Daflon 500 mg in type 2 diabetic female patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rizk</surname><given-names>Sherine Maher</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Sabri</surname><given-names>Nagwa Ali</given-names></name><email>nagwa_sabri@yahoo.com</email><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">⁎</xref></contrib></contrib-group><aff id="aff1"><label>a</label>Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt</aff><aff id="aff2"><label>b</label>Department of Clinical Pharmacy, Ain Shams University, Cairo, Egypt</aff><author-notes><corresp id="cor1"><label>⁎</label>Corresponding author. <email>nagwa_sabri@yahoo.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>7</day><month>8</month><year>2009</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="epub"><day>7</day><month>8</month><year>2009</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2009</year></pub-date><volume>17</volume><issue>3</issue><fpage>199</fpage><lpage>207</lpage><history><date date-type="received"><day>15</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>10</day><month>5</month><year>2009</year></date></history><permissions><copyright-statement>© 2009 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder></copyright-holder></permissions><abstract><sec><title>Background</title><p>The incidence of cardiovascular disease in patients with type 2 diabetes mellitus is approximately twice as high as in the non-diabetic population.</p></sec><sec><title>Aim</title><p>To investigate the hypoglycemic and hypocholesterolemic effects of Daflon<sup>®</sup> 500 mg (DF) administration together with its tolerability and efficacy in reducing the cardiovascular metabolic risk factors in female patients with type 2 diabetes.</p></sec><sec><title>Methods</title><p>In a well-adequate controlled single-blinded randomized parallel design the tolerability and the efficacy of Daflon<sup>®</sup> (500 mg) either alone or with oral hypoglycemic, twice daily for 45 days, was studied in 36 female patients with type 2 diabetes.</p></sec><sec><title>Results</title><p>None of the patients in the studied groups were reported to have any adverse events throughout the treatment period (45 days), liver and kidney function tests were within normal limits and there was no significant difference between the pre-treatment (day 0) and post-treatment (day 45) values. Female patients receiving Daflon<sup>®</sup> either alone or with oral hypoglycemic showed significant decrease in serum glucose; fructosamine; total cholesterol; LDL–cholesterol; triglycerides; malondialdehydes (as index of lipid peroxidation) and C-reactive protein (CRB) levels along with increase in the levels of nitric oxide and blood glutathione.</p></sec><sec><title>Conclusion</title><p>This study has shown that Daflon<sup>®</sup> (500 mg, twice daily for 45 days) is helpful in reducing glucose level and the risk of cardiovascular disease in type 2 diabetic patients.</p></sec><sec><title>Recommendation</title><p>Further clinical trials are essential for strengthening the evidence base on the role of this drug in the cardiovascular risk in diabetic patients.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Diabetes mellitus</kwd><kwd>Daflon<sup>®</sup></kwd><kwd>Cardiovascular disease risk</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003193 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 003193 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:3731024
|texte= Evaluation of clinical activity and safety of Daflon 500 mg in type 2 diabetic female patients
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:23964162" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |